Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine-Reference-Cited by-同舟云学术

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

Published:2013-08 Issue:8 Volume:3 Page:e130-e130
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Maeda T,Hosen N,Fukushima K,Tsuboi A,Morimoto S,Matsui T,Sata H,Fujita J,Hasegawa K,Nishida S,Nakata J,Nakae Y,Takashima S,Nakajima H,Fujiki F,Tatsumi N,Kondo T,Hino M,Oji Y,Oka Y,Kanakura Y,Kumanogoh A,Sugiyama H

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201329.pdf

Reference8 articles.

1. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.

2. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236–242.

3. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115–2121.

4. Miwa H, Beran M, Saunders GF . Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405–409.

5. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Wilms’ tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives;Human Vaccines & Immunotherapeutics;2023-12-26

2. Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives;Journal of Clinical Medicine;2022-01-04

3. WT1 epitope‑specific IgG and IgM antibodies for immune‑monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine;Oncology Letters;2022-01-03

4. Identification of mouse helper epitopes for WT1-specific CD4+ T cells;Cancer Immunology, Immunotherapy;2021-07-16

5. Immunotherapy in Acute Myeloid Leukemia: Where We Stand;Frontiers in Oncology;2021-05-10